Content Currently Unavailable
Article | 2026 Clinical Trials at the Summit
Migaldendranib Shows Substantial Injection Reduction
Early phase 2 data in DME and nAMD showed approximately 80% reduction in intravitreal injection burden compared with pre-study treatment.
Content Currently Unavailable







